These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8555081)

  • 1. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor.
    Shima M; Nakai H; Scandella D; Tanaka I; Sawamoto Y; Kamisue S; Morichika S; Murakami T; Yoshioka A
    Br J Haematol; 1995 Nov; 91(3):714-21. PubMed ID: 8555081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
    Shima M; Scandella D; Yoshioka A; Nakai H; Tanaka I; Kamisue S; Terada S; Fukui H
    Thromb Haemost; 1993 Mar; 69(3):240-6. PubMed ID: 7682339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
    Saenko EL; Shima M; Rajalakshmi KJ; Scandella D
    J Biol Chem; 1994 Apr; 269(15):11601-5. PubMed ID: 7512568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor.
    Kallas A; Pooga M; Benhida A; Jacquemin M; Saint-Remy JM
    Thromb Res; 2002 Sep; 107(6):291-302. PubMed ID: 12565716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
    Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
    Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
    Yada K; Nogami K; Shima M
    Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect.
    Nogami K; Shima M; Nakai H; Tanaka I; Suzuki H; Morichika S; Shibata M; Saenko EL; Scandella D; Giddings JC; Yoshioka A
    Br J Haematol; 1999 Oct; 107(1):196-203. PubMed ID: 10520041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain.
    Nogami K; Shima M; Giddings JC; Takeyama M; Tanaka I; Yoshioka A
    Int J Hematol; 2007 May; 85(4):317-22. PubMed ID: 17483075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.
    Saenko EL; Scandella D
    J Biol Chem; 1997 Jul; 272(29):18007-14. PubMed ID: 9218428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism.
    Nogami K; Shima M; Nishiya K; Sakurai Y; Tanaka I; Giddings JC; Saenko EL; Yoshioka A
    Thromb Haemost; 2002 Mar; 87(3):459-65. PubMed ID: 11916079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
    Saenko EL; Shima M; Gilbert GE; Scandella D
    J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease.
    Tout H; Obert B; Houllier A; Fressinaud E; Rothschild C; Meyer D; Girma JP
    Thromb Haemost; 2000 Feb; 83(2):274-81. PubMed ID: 10739386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes.
    Gilles JG; Lavend'homme R; Peerlinck K; Jacquemin MG; Hoylaerts M; Jorieux S; Mazurier C; Vermylen J; Saint-Remy JM
    Thromb Haemost; 1999 Jul; 82(1):40-5. PubMed ID: 10456452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor.
    Saenko EL; Scandella D
    J Biol Chem; 1995 Jun; 270(23):13826-33. PubMed ID: 7775440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.
    Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
    Blood; 2007 Dec; 110(13):4234-42. PubMed ID: 17848617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies.
    Scandella D
    Vox Sang; 1999; 77 Suppl 1():17-20. PubMed ID: 10529680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
    J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site.
    Pratt KP; Qian J; Ellaban E; Okita DK; Diethelm-Okita BM; Conti-Fine B; Scott DW
    Thromb Haemost; 2004 Sep; 92(3):522-8. PubMed ID: 15351848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction.
    Batlle J; Lourés E; Vila P; Hernández MC; Méndez JA; Torea J; Rendal E; Couselo MJ; Filgueira A; López Fernández MF
    Ann Hematol; 1997 Sep; 75(3):111-5. PubMed ID: 9368480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.